Literature DB >> 27052442

Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis.

Qiaomei Zheng1, Hongluan Mao1, Ying Xu1, Jing Zhao1, Xuan Wei1, Peishu Liu2.   

Abstract

PURPOSE: To investigate whether postoperative GnRH agonist (GnRH-a) treatment can prevent endometriosis recurrence.
METHODS: This meta-analysis searched PubMed, Embase and Cochrane Library for relevant studies published online before June 2015. Seven randomized controlled trials including 328 patients with postoperative GnRH-a treatment and 394 patients in control group were included in the meta-analysis. In the meta-analysis, the recurrence rate of GnRH-a group compared with control group was evaluated with odds ratio (OR) and its 95 % confidence interval (CI). Heterogeneity, small study effect and publication bias were, respectively, assessed using Higgins I (2), sensitivity analysis and funnel plot.
RESULTS: Postoperative GnRH-a treatment for endometriosis (pooled OR = 0.71; 95 % CI 0.52-0.96) was superior to expectant or placebo treatment in prevention of the recurrence. The recurrence rate decreased significantly in patients who received 6 months GnRH-a treatment (pooled OR = 0.59, 95 % CI 0.38-0.90), whereas no significant difference of recurrence rate existed between patients with 3 months post-surgical GnRH-a therapy and the control group (pooled OR = 0.87, 95 % CI 0.56-1.34). No significant heterogeneity and small study effect were found in the meta-analysis. However, publication bias did existed in the present meta-analysis.
CONCLUSIONS: Longer-term (6 months) postoperative administration of GnRH-a can decrease the recurrence risk of endometriosis, whereas 3 months duration of GnRH-a therapy makes no significant difference in preventing the recurrence of endometriosis. Therefore, instead of a 3 month therapy, the duration of the postoperative administration should be longer enough (6 months) to prevent the recurrence of endometriosis.

Entities:  

Keywords:  Endometriosis; GnRH agonist; Meta-analysis; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 27052442     DOI: 10.1007/s00404-016-4085-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  Intravesical endometriosis mimicking bladder cancer.

Authors:  Chin-Ru Ker; Kun-Ling Lin; Cheng-Yu Long
Journal:  Int Urogynecol J       Date:  2016-06-16       Impact factor: 2.894

2.  Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020).

Authors:  Stefanie Burghaus; Sebastian D Schäfer; Matthias W Beckmann; Iris Brandes; Christian Brünahl; Radek Chvatal; Jan Drahoňovský; Wojciech Dudek; Andreas D Ebert; Christine Fahlbusch; Tanja Fehm; Peter Martin Fehr; Carolin C Hack; Winfried Häuser; Katharina Hancke; Volker Heinecke; Lars-Christian Horn; Christian Houbois; Christine Klapp; Heike Kramer; Harald Krentel; Jan Langrehr; Heike Matuschewski; Ines Mayer; Sylvia Mechsner; Andreas Müller; Armelle Müller; Michael Müller; Peter Oppelt; Thomas Papathemelis; Stefan P Renner; Dietmar Schmidt; Andreas Schüring; Karl-Werner Schweppe; Beata Seeber; Friederike Siedentopf; Horia Sirbu; Daniela Soeffge; Kerstin Weidner; Isabella Zraik; Uwe Andreas Ulrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

3.  A Preliminary Study on the Effects of Black Cohosh Preparations on Bone Metabolism of Rat Models With GnRH-a-Induced Peri-Menopausal Symptoms.

Authors:  Zhenyue Qin; Zhiyong Dong; Junling Liu; Ahong Zhong; Mingyue Bao; Huihui Wang; Hongxia Yu; Shoufeng Zhang; Wendi Zhang; Li Shen; Jie Wu; Jiming Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

4.  Efficacy of Post-Operative Medication to Prevent Recurrence of Endometrioma: Cyclic Oral Contraceptive (OC) After Gonadotropin-Releasing Hormone (GnRH) Agonist Versus Dienogest.

Authors:  Seung-Hye Choi; Sung Eun Kim; Hyun Hye Lim; Dong-Yun Lee; DooSeok Choi
Journal:  J Korean Med Sci       Date:  2022-07-04       Impact factor: 5.354

Review 5.  Risk factors for ovarian endometrioma recurrence following surgical excision: a systematic review and meta‑analysis.

Authors:  Danni Jiang; Xuxing Zhang; Jiaqi Shi; Dongmei Tao; Xiaocui Nie
Journal:  Arch Gynecol Obstet       Date:  2021-06-20       Impact factor: 2.344

6.  GnRH-a-Induced Perimenopausal Rat Modeling and Black Cohosh Preparations' Effect on Rat's Reproductive Endocrine.

Authors:  Jiming Chen; Huihui Wang; Zhiyong Dong; Junling Liu; Zhenyue Qin; Mingyue Bao; Hongxia Yu; Shoufeng Zhang; Wendi Zhang; Chunjian Qi; Jie Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

7.  Analysis of recurrence factors associated with conservative surgery for ovarian-type endometriosis.

Authors:  Gu Huang; Xiang Fan; Pengfeng Zhu
Journal:  Ann Transl Med       Date:  2022-03

8.  Characteristics and long-term outcomes of perineal endometriosis: A retrospective study.

Authors:  Yu Liu; Ruyu Pi; Hong Luo; Wei Wang; Xia Zhao; Xiaorong Qi
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

9.  A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain.

Authors:  Sallwa M Alshehre; Sheila Duffy; Georgina Jones; William L Ledger; Mostafa Metwally
Journal:  Reprod Biol Endocrinol       Date:  2020-04-14       Impact factor: 5.211

10.  Malignant risk of pelvic mass after hysterectomy for adenomyosis or endometriosis.

Authors:  Xiaopei Chao; Yang Liu; Mingliang Ji; Shu Wang; Honghui Shi; Qingbo Fan; Jinghe Lang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.